drugset / Trial / NCT00788177
Subretinal Macugen® for Neovascular Age-Related Macular Degeneration
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the efficacy of pegaptanib (Macugen®) for neovascular (exudative) age-related macular degeneration (AMD) when the first dose is administered to the submacular space instead of vitreous body in cases when previous state-of-the-art treatment for the AMD was deemed ineffective.
Timeline
- Start
- 2008-11
- Primary completion
- 2012-03
- Completion
- 2012-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | pegaptanib sodium | Aptamer | — | Other |